Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Theragen EtexLtd

KOSDAQ:A066700
Snowflake Description

Proven track record and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A066700
KOSDAQ
₩233B
Market Cap
  1. Home
  2. KR
  3. Pharmaceuticals & Biotech
Company description

Theragen Etex Co.,Ltd., a pharmaceutical company, engages in the research and development, production, and sale of various drugs in the fields of respiratory, digestive, and circulatory diseases. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • Theragen EtexLtd has significant price volatility in the past 3 months.
A066700 Share Price and Events
7 Day Returns
16%
KOSDAQ:A066700
8.1%
KR Pharmaceuticals
1.9%
KR Market
1 Year Returns
-27.1%
KOSDAQ:A066700
-20.5%
KR Pharmaceuticals
-21.8%
KR Market
A066700 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Theragen EtexLtd (A066700) 16% -8% -7.2% -27.1% 27.4% -7.2%
KR Pharmaceuticals 8.1% 7.4% -2.9% -20.5% -3.4% 18.9%
KR Market 1.9% -14.7% -19.6% -21.8% -19.8% -22%
1 Year Return vs Industry and Market
  • A066700 underperformed the Pharmaceuticals industry which returned -20.5% over the past year.
  • A066700 underperformed the Market in Korea (Republic of) which returned -21.8% over the past year.
Price Volatility
A066700
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Theragen EtexLtd undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Theragen EtexLtd. This is due to cash flow or dividend data being unavailable. The share price is ₩7620.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Theragen EtexLtd's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Theragen EtexLtd's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KOSDAQ:A066700 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in KRW ₩1,432.00
KOSDAQ:A066700 Share Price ** KOSDAQ (2020-04-03) in KRW ₩7620
Korea (Republic of) Pharmaceuticals Industry PE Ratio Median Figure of 53 Publicly-Listed Pharmaceuticals Companies 23.75x
Korea (Republic of) Market PE Ratio Median Figure of 1,311 Publicly-Listed Companies 12.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Theragen EtexLtd.

KOSDAQ:A066700 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KOSDAQ:A066700 Share Price ÷ EPS (both in KRW)

= 7620 ÷ 1,432.00

5.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Theragen EtexLtd is good value based on earnings compared to the KR Pharmaceuticals industry average.
  • Theragen EtexLtd is good value based on earnings compared to the Korea (Republic of) market.
Price based on expected Growth
Does Theragen EtexLtd's expected growth come at a high price?
Raw Data
KOSDAQ:A066700 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 5.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Korea (Republic of) Pharmaceuticals Industry PEG Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 0.98x
Korea (Republic of) Market PEG Ratio Median Figure of 356 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Theragen EtexLtd, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Theragen EtexLtd's assets?
Raw Data
KOSDAQ:A066700 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in KRW ₩4,452.65
KOSDAQ:A066700 Share Price * KOSDAQ (2020-04-03) in KRW ₩7620
Korea (Republic of) Pharmaceuticals Industry PB Ratio Median Figure of 77 Publicly-Listed Pharmaceuticals Companies 1.71x
Korea (Republic of) Market PB Ratio Median Figure of 1,954 Publicly-Listed Companies 0.84x
KOSDAQ:A066700 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KOSDAQ:A066700 Share Price ÷ Book Value per Share (both in KRW)

= 7620 ÷ 4,452.65

1.71x

* Primary Listing of Theragen EtexLtd.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Theragen EtexLtd is good value based on assets compared to the KR Pharmaceuticals industry average.
X
Value checks
We assess Theragen EtexLtd's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Theragen EtexLtd has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Theragen EtexLtd expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Theragen EtexLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Theragen EtexLtd expected to grow at an attractive rate?
  • Unable to compare Theragen EtexLtd's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Theragen EtexLtd's earnings growth to the Korea (Republic of) market average as no estimate data is available.
  • Unable to compare Theragen EtexLtd's revenue growth to the Korea (Republic of) market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KOSDAQ:A066700 Future Growth Rates Data Sources
Data Point Source Value (per year)
Korea (Republic of) Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 21.6%
Korea (Republic of) Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 10.7%
Korea (Republic of) Market Earnings Growth Rate Market Cap Weighted Average 27.8%
Korea (Republic of) Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KOSDAQ:A066700 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in KRW Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KOSDAQ:A066700 Past Financials Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income *
2019-12-31 138,083 24 43,646
2019-09-30 137,076 -11,740 -3,218
2019-06-30 133,374 -16,736 -6,198
2019-03-31 121,750 -20,549 -10,334
2018-12-31 117,475 -18,575 -10,218
2018-09-30 112,293 -3,775 -488
2018-06-30 108,914 3,982 1,650
2018-03-31 110,585 5,716 743
2017-12-31 107,592 1,777 1,274
2017-09-30 107,268 -3,091 -1,617
2017-06-30 103,572 -4,689 -154
2017-03-31 99,384 -6,650 534

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Theragen EtexLtd is high growth as no earnings estimate data is available.
  • Unable to determine if Theragen EtexLtd is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KOSDAQ:A066700 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Theragen EtexLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A066700 Past Financials Data
Date (Data in KRW Millions) EPS *
2019-12-31 1,432.00
2019-09-30 -105.59
2019-06-30 -203.59
2019-03-31 -340.06
2018-12-31 -338.00
2018-09-30 -16.47
2018-06-30 56.30
2018-03-31 26.25
2017-12-31 45.00
2017-09-30 -56.91
2017-06-30 -5.48
2017-03-31 18.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Theragen EtexLtd will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Theragen EtexLtd is trading at Theragen EtexLtd'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Theragen EtexLtd's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Theragen EtexLtd's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Korea (Republic of) market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Korea (Republic of) market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Theragen EtexLtd has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Theragen EtexLtd performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Theragen EtexLtd's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Theragen EtexLtd has delivered over 20% year on year earnings growth in the past 5 years.
  • Theragen EtexLtd has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Theragen EtexLtd has become profitable in the last year making it difficult to compare the KR Pharmaceuticals industry average.
Earnings and Revenue History
Theragen EtexLtd's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Theragen EtexLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A066700 Past Revenue, Cash Flow and Net Income Data
Date (Data in KRW Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 138,083.45 43,645.67 28,848.38 4,099.09
2019-09-30 137,076.19 -3,218.37 29,092.59 4,157.19
2019-06-30 133,374.43 -6,198.26 28,618.30 4,151.55
2019-03-31 121,749.83 -10,334.33 28,378.74 4,206.61
2018-12-31 117,474.51 -10,217.64 27,793.91 4,170.87
2018-09-30 112,293.45 -488.50 26,502.60 5,098.39
2018-06-30 108,914.36 1,649.80 27,313.84 4,543.25
2018-03-31 110,585.33 742.57 28,186.74 3,544.71
2017-12-31 107,591.87 1,273.73 28,288.26 3,365.97
2017-09-30 107,268.35 -1,616.80 29,704.02 2,505.86
2017-06-30 103,571.66 -153.62 28,351.88 2,838.40
2017-03-31 99,384.06 533.70 26,163.10 3,805.66
2016-12-31 101,283.31 2,042.76 25,228.06 3,943.75
2016-09-30 97,941.51 -6,495.34 27,172.42 4,086.71
2016-06-30 99,460.08 -6,824.25 29,037.76 3,768.37
2016-03-31 100,873.29 -6,550.26 30,467.21 3,701.75
2015-12-31 98,884.31 -6,802.94 31,524.29 3,632.37
2015-09-30 90,006.31 3,664.86 26,569.97 3,231.43
2015-06-30 87,809.85 3,975.15 25,916.62 3,350.47
2015-03-31 86,830.72 1,931.56 26,544.06 3,070.13
2014-12-31 89,742.93 1,479.23 26,798.11 3,078.79
2014-09-30 98,081.62 722.77 28,307.23 3,833.76
2014-06-30 96,557.84 -420.98 26,789.54 3,826.97
2014-03-31 96,706.06 1,208.37 25,111.29 4,101.27
2013-12-31 90,730.51 1,326.85 23,345.55 4,210.25
2013-09-30 78,661.94 -3,184.31 24,011.68 3,391.51
2013-06-30 85,136.76 -4,103.85 24,519.65 3,854.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Theragen EtexLtd has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Theragen EtexLtd used its assets more efficiently than the KR Pharmaceuticals industry average last year based on Return on Assets.
  • Theragen EtexLtd has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Theragen EtexLtd's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Theragen EtexLtd has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Theragen EtexLtd's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Theragen EtexLtd's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Theragen EtexLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Theragen EtexLtd's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Theragen EtexLtd's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Theragen EtexLtd Company Filings, last reported 3 months ago.

KOSDAQ:A066700 Past Debt and Equity Data
Date (Data in KRW Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 145,326.39 46,053.37 11,068.56
2019-09-30 93,790.82 45,045.41 10,133.62
2019-06-30 94,028.05 45,660.87 11,269.61
2019-03-31 88,662.12 44,767.92 13,185.47
2018-12-31 89,786.23 44,070.61 16,250.81
2018-09-30 97,081.70 34,926.24 7,674.07
2018-06-30 99,163.11 26,979.00 9,106.26
2018-03-31 94,139.76 25,800.90 8,034.09
2017-12-31 93,649.48 27,859.74 7,426.49
2017-09-30 84,130.37 36,469.88 4,911.54
2017-06-30 84,767.15 33,503.81 5,150.86
2017-03-31 83,447.50 33,385.97 5,024.19
2016-12-31 79,020.85 36,057.47 8,270.86
2016-09-30 78,568.45 32,418.11 6,558.73
2016-06-30 77,808.37 29,949.09 11,246.37
2016-03-31 78,723.18 18,666.53 13,210.35
2015-12-31 75,900.08 19,144.42 11,710.03
2015-09-30 85,408.25 19,886.95 11,339.57
2015-06-30 84,759.83 19,686.57 17,583.84
2015-03-31 82,550.01 17,797.03 13,729.94
2014-12-31 81,996.41 15,866.52 14,738.85
2014-09-30 79,953.90 14,848.35 13,817.79
2014-06-30 79,146.32 14,212.19 14,670.14
2014-03-31 80,082.31 17,284.26 17,701.46
2013-12-31 79,665.88 15,292.35 16,622.55
2013-09-30 78,492.87 16,041.56 17,769.54
2013-06-30 74,617.03 17,603.09 14,045.45
  • Theragen EtexLtd's level of debt (31.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (19.4% vs 31.7% today).
  • Debt is not well covered by operating cash flow (0.1%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 1.4x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Theragen EtexLtd's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Theragen EtexLtd has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Theragen EtexLtd's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Theragen EtexLtd dividends.
If you bought ₩2,000 of Theragen EtexLtd shares you are expected to receive ₩0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Theragen EtexLtd's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Theragen EtexLtd's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KOSDAQ:A066700 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Korea (Republic of) Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 0.9%
Korea (Republic of) Market Average Dividend Yield Market Cap Weighted Average of 908 Stocks 2.9%
Korea (Republic of) Minimum Threshold Dividend Yield 10th Percentile 0.6%
Korea (Republic of) Bottom 25% Dividend Yield 25th Percentile 1.2%
Korea (Republic of) Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Theragen EtexLtd has not reported any payouts.
  • Unable to verify if Theragen EtexLtd's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Theragen EtexLtd's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Theragen EtexLtd has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Theragen EtexLtd's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Theragen EtexLtd afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Theragen EtexLtd has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Theragen EtexLtd's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jin-Yeob Go
AGE 67
CEO Bio

Mr. Ko Jin-Up serves as Chief Executive Officer of Theragen Etex Co.,Ltd. Mr. Ko served as Chief Executive Officer of Jinup Pharmaceutical Co., Ltd. and Representative of ChangHo Pharmaceutical Co., Ltd. Mr. Ko serves as Vice Chairperson of Leadpharm Co., Ltd.

CEO Compensation
  • Insufficient data for Jin-Yeob to compare compensation growth.
  • Insufficient data for Jin-Yeob to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Jin-Yeob Go

TITLE
Chief Executive Officer
AGE
67

Cho Hyung-Seok

TITLE
Managing Director
AGE
64
TENURE
15.8 yrs
Board of Directors

Jung-Geun Lee

TITLE
Director
AGE
73

Sang-Hwoi Park

TITLE
Director
AGE
60

Yoon Sung-Wook

TITLE
Director
AGE
58

Soo-In Kim

TITLE
Director
AGE
68

Wang-Jae Lee

TITLE
Director
AGE
64

Kyu-Won Ji

TITLE
Director
AGE
71

Kim Byung-Ha

TITLE
Director
AGE
59

Kun-Sik Choi

TITLE
Director
AGE
74
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₩) Value (₩)
X
Management checks
We assess Theragen EtexLtd's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Theragen EtexLtd has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Theragen Etex Co.,Ltd., a pharmaceutical company, engages in the research and development, production, and sale of various drugs in the fields of respiratory, digestive, and circulatory diseases. It offers prescription medicines, OTC medicines, and health functional foods. The company was formerly known as Theragen Co., Ltd. and changed its name to Theragen Etex Co.,Ltd. in July 2010. Theragen Etex Co.,Ltd. was founded in 1987 and is headquartered in Seoul, South Korea.

Details
Name: Theragen Etex Co.,Ltd.
A066700
Exchange: KOSDAQ
Founded: 1987
₩232,874,065,620
30,560,901
Website: http://www.etexpharm.co.kr
Address: Theragen Etex Co.,Ltd.
Daegwan Building,
5th Floor,
Seoul,
South Korea
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KOSDAQ A066700 Common Stock KOSDAQ KR KRW 27. May 2004
Number of employees
Current staff
Staff numbers
0
Theragen EtexLtd employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 14:31
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/03/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.